Evidence map›Paper›PMID 27123050›Full record

ArticleOncology letters2016

Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review.

Pengfei Liu, Qingyu Yao, N A Li, Yongliang Liu, Yuguo Wang, Meng Li, Zefu Li, Jianmin Li, Gang Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Schwannomas of Brain and Spinal Cord.Advances in experimental medicine and biology · 2023
    Article
  3. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.International journal of molecular sciences · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pengfei LiuDepartment of Neurosurgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China; Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Qingyu YaoDepartment of Neurosurgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
N A LiDepartment of Nuclear Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Yongliang LiuDepartment of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Yuguo WangDepartment of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Meng LiDepartment of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Zefu LiDepartment of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Jianmin LiDepartment of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
Gang LiDepartment of Neurosurgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Binzhou Medical University · CNQilu Hospital of Shandong University · CNBinzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current case study aimed to explore the efficacy of a low-dose bevacizumab regimen in inhibiting tumor growth and minimizing adverse effects. A 55-year-old man with neurofibromatosis type 2 (NF2) suffered bilateral vestibular schwannomas (VS) measuring 5.25 and 2.54 cm

Indexed as

bevacizumabneurofibromatosis type 2vascular endothelial growth factorvestibular schwannomas

Identifiers

PMID27123050
PMCPMC4840682
OpenAlexW2302362713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.